Proteasomes are broadly expressed key components of the ubiquitin-dependent protein
degradation pathway containing catalytically active subunits (β1, β2, and β5). LMP7 (β5i) is …

Abstract Large multifunctional peptidase 7 (LMP7/β5i/PSMB8) is a proteolytic subunit of the
immunoproteasome, which is predominantly expressed in normal and malignant …

Selective inhibitors for the human immunoproteasome LMP7 (β5i) subunit over the
constitutive proteasome hold promise for the treatment of autoimmune and inflammatory …

Summary PR‐924 is an LMP‐7‐selective tripeptide epoxyketone proteasome inhibitor that
covalently modifies proteasomal N‐terminal threonine active sites. In the present study, we …

Building upon the success of bortezomib (VELCADE) and carfilzomib (KYPROLIS), the
design of a next generation of inhibitors targeting specific subunits within the …

Mammalian genomes encode seven catalytic proteasome subunits, namely, β1c, β2c, β5c
(assembled into constitutive 20S proteasome core particles), β1i, β2i, β5i (incorporated into …

The immunoproteasome, having been linked to neurodegenerative diseases and
hematological cancers, has been shown to play an important role in MHC class I antigen …

The proteasome is the central component of the main cellular protein degradation pathway.
During the past four decades, the critical function of the proteasome in numerous …

Proteasome inhibition is a validated strategy for therapy of multiple myeloma, but this
disease remains challenging as relapses are common, and often associated with increasing …

While the constitutive, 26S proteasome plays an important role in regulating many important
cellular processes, a variant form known as the immunoproteasome is thought to primarily …